The effectiveness of ICIs in ovarian cancer is limited; however, these findings based on the SFRP2+ fibroblast signature provide new insights for the assessment of immunotherapy and offer guidance on whether OC patients are likely to benefit from such treatments. This evidence concerns the gene SFRP2 and ovarian cancer.